State-of-the-Art PaperEisenmenger Syndrome: A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension
Under an Elsevier user license
open archive
Key Words
Eisenmenger syndrome
pulmonary arterial hypertension
physiopathology
therapy
Abbreviations and Acronyms
ASD
atrial septal defect
CHD
congenital heart defects
ES
Eisenmenger syndrome
IPAH
idiopathic pulmonary arterial hypertension
PAH
pulmonary arterial hypertension
PVR
pulmonary vascular resistance
VSD
ventricular septal defect
Cited by (0)
Prof. Galiè has served on advisory boards for Pfizer, Actelion, Bayer Schering, Encysive, Myogen, GlaxoSmithKline, Eli Lilly, and Mondobiotech, and has received lecture fees from Actelion and Bayer Schering. Prof. Beghetti has served on advisory boards for Pfizer, Actelion, Bayer Schering, Encysive, GlaxoSmithKline, INO Therapeutics, Eli Lilly, and Mondobiotech, and has received lecture fees from Actelion, Encysive, and Bayer Schering. Dr. Galiè's Institute has received grant support from Pfizer, Actelion, Bayer Schering, Encysive, United Therapeutics, Eli Lilly, and Myogen.
Copyright © 2009 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.